Incyte Corporation (INCY) : The value of composite uptick trades was $51.64 million, whereas, the value of composite downtick trades was $65.9 million. The uptick to downtick ratio stood at 0.78 with a negative money flow of ($14.26) Million during Wednesdays trading session. The block trades money flow was negative ($12.12 million).The uptick to the downtick ratio of 0.24 in block trades signals that the large investors have utilized the rise in the stock to sell.The uptick transaction value stood at $3.77 million. The transaction of the trades on downticks amounted to $15.89 million, which confirms investors selling on the strength of price. Incyte Corporation (INCY) gained 376 cents at $92.83, an increase of 4.22% over the previous days close.
Shares of Incyte Corporation rose by 7.48% in the last five trading days and 14.59% for the last 4 weeks. Incyte Corporation is up 18.36% in the last 3-month period. Year-to-Date the stock performance stands at -14.06%.
Incyte Corporation (INCY) : The consensus on Incyte Corporation (INCY) based on 14 analyst recommendation on the company stock is 1.25, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 11 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 analyst believes that the stock is a Buy, which can produce decent returns in the future. 1 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
Incyte Corporation (NASDAQ:INCY): The stock opened at $94.98 and touched an intraday high of $95.39 on Wednesday. During the day, the stock corrected to an intraday low of $91.39, however, the bulls stepped in and pushed the price higher to close in the green at $93.2 with a gain of 4.64% for the day. The total traded volume for the day was 2,652,619. The stock had closed at $89.07 in the previous trading session.
Incyte Corporation is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat serious unmet medical needs. The Companys compound JAKAFI (ruxolitinib) also known as INCB18424 and INC424 is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or highrisk myelofibrosis (MF) including primary MF postpolycythemia vera MF and postessential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor LY3009104 (INCB28050) , which is subject to a collaboration agreement with Eli Lilly and Company in , which Lilly received development and commercialization rights f